FDA authorizes an expanded access treatment protocol after the oral RAS(ON) inhibitor doubled survival for metastatic patients in a phase 3 trial.

Approval was based on findings from the phase 3 VERITAC-2 trial showing significantly improved PFS for patients with ESR1-mutated disease.

Researchers combined electronic sensors with human islet cells to create living ‘cyborg’ organoids transmitting troves of ...

A new FDA regulatory pathway could accelerate approval of psychedelic therapies for resistant depression and PTSD, and ...

If future trials continue to show positive results, the drug may provide a pain-relief option that lacks the risks of long-term NSAID use.

The largest US study to date on teen cannabis uses shows that cannabis use during adolescence may hinder cognitive improvement over time.

Using a more pragmatic classification system than the current standard provided clearer discrimination between disease ...

From a Romanian pharmacist forced to dispense to Maltese GPs afraid of lawsuits, the barriers to change run far deeper than ...

Wheat allergy in young children is uncommon, but many referred children tolerate wheat protein or have a reaction only to ...

RFK Jr and Joe Rogan use them to heal, and NASA wants to put one in the astropharmacy. But without extensive data on humans, ...

To have a drug that has an impact on mortality, it’s of huge interest and a benefit for patients with ILD,’ said rheumatologist Voon Ong, MBBS, PhD, who was not involved in the study.

The FDA has approved Auvelity for AD agitation. The combination of dextromethorphan and bupropion is the first oral non-antipsychotic approved for this indication.